We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Major Biomedical Research Reagents Supplier Licences Chromatrap ChIP Technology

Major Biomedical Research Reagents Supplier Licences Chromatrap ChIP Technology content piece image
Read time: Less than a minute

Chromatrap® announces that BioLegend, a major US-based manufacturer and supplier of reagents and kits for biomedical research, has chosen their novel solid-state ChIP technology to power a new range of faster and more efficient chromatin immunoprecipitation kits. 


These new kits will combine BioLegend's expertise in developing the Go-ChIP-Grade™ antibodies that are validated for ChIP assays with the patented solid-state immunocapture surface at the heart of every Chromatrap® product. This combination will result in a market-leading range of ChIP-sequencing kits, offering researchers an opportunity to perform faster, simpler and more sensitive assays for their epigenetics research. 


With the rapid growth of ChIP-seq as a technique to interrogate the epigenetic landscape, both companies anticipate this class of kit will meet a critical need in the market.


Product Development Manager for Chromatrap®, Dr Amy Beynon said "The wide distribution network offered by BioLegend is an ideal way to expand the reach of our proven novel solid-state ChIP technology. Access to important geographical markets where BioLegend is an established and trusted supplier forms the core of our relationship. We look forward to supporting many more researchers as BioLegend expands the usage of Chromatrap technology across these markets."


Together the two companies aim to make BioLegend's Go-ChIP-Grade™ antibodies and ChIP kits incorporating Chromatrap technology the method of choice for ChIP-sequencing in the future.


The Chromatrap technology is patented in the USA, Australia, Japan, UK and China by parent company - Porvair. The collaboration with BioLegend covers access to Chromatrap spin columns and proprietary buffers for use in BioLegend's new ChIP-sequencing kits in all geographic territories.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.